Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | CSK | P41240 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677434 | 0.99 | KDR (0.61) | KDREGFRERBB2AURKASRC | |
| Hydrochloric Acid SCHEMBL6449945 | 0.94 | KDR (0.69) | KDREGFRSRC | |
| SCHEMBL3745277 | 0.92 | KDR (0.58) | KDREGFRERBB2SRCEPHB4 | |
| SCHEMBL3674395 | 0.90 | KDR (0.49) | KDREGFRERBB2AURKASRC | |
| SCHEMBL3675120 | 0.89 | KDR (0.48) | KDREGFRERBB2AURKASRC | |
| SCHEMBL3669463 | 0.89 | KDR (0.67) | KDREGFRERBB2AURKASRC | |
| SCHEMBL3671075 | 0.88 | KDR (0.66) | KDREGFRAURKASRCFGFR1 | |
| SCHEMBL3738451 | 0.86 | KDR (0.62) | KDREGFRERBB2AURKASRC | |
| SCHEMBL3672100 | 0.85 | KDR (0.61) | KDREGFRERBB2AURKASRC | |
| SCHEMBL3677227 | 0.85 | KDR (0.55) | KDREGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | claimed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | claimed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | KDR 2192/4885EGFR 2315/4885ERBB2 1833/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | KDR 825/4885EGFR 155/4885ERBB2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.